In breast cancer, the GR phosphorylation at Ser134 was mandatory for the interaction with PELP1, and it was suggested that targeting phospho-Ser134 GR in certain cases of triple-negative breast cancer may be a useful therapeutical strategy [85, 86]. This evidence concerns the gene NR3C1 and triple-negative breast carcinoma.